SCHEMBL2937079

SCHEMBL2937079

CC1C(=O)N(c2ccc(OC(F)(F)F)cc2)C(=O)N1Cc1ccncc1NC(=O)C1CCCCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.41
GSK3A P49840 1/20 0.41
CHRM4 P08173 5/20 0.40
LMNA P02545 1/20 0.39
HTT P42858 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
IGF1R P08069 1/20 0.39
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KDM4E B2RXH2 2/20 0.35
HSD17B10 Q99714 1/20 0.35
EPHX2 P34913 3/20 0.35
ALDH1A1 P00352 1/20 0.35
POLB P06746 1/20 0.35
ACHE P22303 1/20 0.35
MAPT P10636 1/20 0.34
MEN1 O00255 1/20 0.34
TP53 P04637 1/20 0.34
MAPK1 P28482 1/20 0.34
KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2931354 0.92 GSK3A (0.41) GSK3BGSK3ACHRM4LMNAHTT
SCHEMBL2933360 0.88 IGF1R (0.42) GSK3BGSK3AIGF1RL3MBTL1POLB
SCHEMBL2942814 0.87 IGF1R (0.39) GSK3BGSK3AIGF1RKDM4EALDH1A1
SCHEMBL2936074 0.87 AOC1 (0.41) IGF1REPHX2
SCHEMBL2939367 0.87 IGF1R (0.43) GSK3BGSK3AIGF1RL3MBTL1TP53
SCHEMBL2940047 0.87 IGF1R (0.55) GSK3BGSK3ALMNAIGF1REPHX2
SCHEMBL2940582 0.85 IGF1R (0.40) LMNAIGF1RALDH1A1POLBMAPT
SCHEMBL2942973 0.84 IGF1R (0.43) GSK3BGSK3AIGF1RTP53GCGR
SCHEMBL2940810 0.84 IGF1R (0.40) IGF1RL3MBTL1TP53
SCHEMBL2938387 0.84 GSK3A (0.41) GSK3BGSK3ACHRM4LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7825115-B2 Cyclic urea compounds, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2010-11-02 US disclosed
EP-1599464-B1 NOVEL CYCLIC UREA DERIVATIVES, PREPARATION METHOD THEREOF AND PHARMACEUTICAL USE OF SAME AS KINASE INHIBITORS AVENTIS PHARMA SA (FR) 2010-09-22 EP disclosed
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors AVENTIS PHARMA S.A. (FR) 2008-05-08 US disclosed
US-7354933-B2 Protein kinase inhibitors; antitumor agents; such as 5-methyl-1-quinol-4-ylmethyl-3-(4-trifluoromethanesulfonylphenyl)imidazolidine-2,4-dione trifluoroacetate AVENTIS PHARMA SA (FR) 2008-04-08 US disclosed
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors AVENTIS PHARMA S.A. (FR) 2004-12-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108654-A1 Cyclic Urea Compounds, Preparation Thereof and Pharmaceutical Use Thereof as Kinase Inhibitors PRKG1, PRKACA, CMPK1 GSK3B 799/4885GSK3A 740/4885CHRM4 4442/4885
US-20040248884-A1 Novel cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors PRKG1, PRKACA, PRKCA GSK3B 702/4885GSK3A 659/4885CHRM4 4393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.